GGrantIndex
← Leaderboards

Yale University

New Haven, CT

Compare ↔
$11,439,367,916
Total funding
9,867
Grants

Funding over time

peak $756.3M · FY2005–26
$1B$750M$500M$250M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
'26

Funding mix

By agency

NIH$10,614,816,556 · 7945
NSF$769,062,378 · 1824
AHRQ$61,368,645 · 50
CDC$40,318,597 · 34
FDA$26,996,870 · 8
NASA$389,397 · 1
DOE$53,958 · 1
SAMHSA$0 · 7

By mechanism

R01$5,600,097,002 · 2608
—$769,505,733 · 1826
U01$641,616,753 · 136
T32$428,081,362 · 91
P01$364,516,682 · 386
R21$324,334,667 · 795

Investigators at Yale University

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Anirvan S. Nandy$4,320,9145 gr2Nicole Deziel$3,662,5716 gr3Kathryn Hawk$3,201,1383 gr4Kenneth Hoehn$2,874,3253 gr5Andres Hidalgo$2,816,5551 gr6Nathan Dale Grubaugh$2,514,5001 gr7Berna Sozen$2,512,5001 gr8Krysten W. Bold$2,421,5101 gr

Emerging Leaders

6–10 yrs in

1John Alvaro$27,723,1101 gr2Allegra Di Bonaventura$21,157,8002 gr3Siyuan Wang$10,299,7229 gr4Zhengxin Cai$10,214,56710 gr5Amy F Arnsten$8,074,2191 gr6Dustin Scheinost$8,044,50611 gr7Rui Chang$7,758,3274 gr8David Pitt$7,740,4065 gr

All-Time

Most funded here, all years

1Michael P Snyder$209,065,56053 gr2Leora Horwitz$172,853,1206 gr3Robert Stanley Sherwin$134,887,21260 gr4Lucila Ohno-Machado$130,482,08735 gr5Nenad Sestan$81,842,29625 gr6Stephen M Strittmatter$76,187,37137 gr7John H Krystal$70,915,88939 gr8Heping Zhang$60,378,42211 gr

Largest grants

Graduate Research Fellowship Program$28,734,420
· FY2011 · EDU
Graduate Research Fellowship Program (GRFP)$27,723,110
· FY2021 · EDU
Graduate Research Fellowship Program (GRFP)$21,111,800
· FY2017 · EDU
ProCAN: Psychosis Risk Outcomes Compound Assessment Network$16,589,886
U01 · FY2025 · MH
ProNET: Psychosis-Risk Outcomes Network$15,918,096
U01 · FY2022 · MH
Insulin Resistance Inten/ention after Stroke (IRIS) Trial$15,609,558
U01 · FY2011 · NS
ProCAN: Psychosis Risk Outcomes Compound Assessment Network$14,993,866
U01 · FY2024 · MH
Center for Innovative Structures and Phenomena$13,600,000
· FY2011 · MPS
Insulin Resistance Intervention after Stroke (IRIS) Trial$13,419,868
U01 · FY2010 · NS
Insulin Resistance Inten/ention after Stroke (IRIS) Trial$13,419,868
U01 · FY2010 · NS
ProNET: Psychosis-Risk Outcomes Network$12,623,656
U01 · FY2021 · MH
Impaired human innate immune cell function in the elderly and immunosuppressed$12,439,964
N01 · FY2011 · AI
The National Drug Abuse Clinical Trials Network: New England Consortium Node$11,916,289
UG1 · FY2024 · DA
ProNET: Psychosis-Risk Outcomes Network$11,636,305
U01 · FY2023 · MH
Insulin Resistance Inten/ention after Stroke (IRIS) Trial$10,887,994
U01 · FY2009 · NS
Insulin Resistance Intervention after Stroke (IRIS) Trial$10,887,994
U01 · FY2009 · NS
ProNET: Psychosis-Risk Outcomes Network$10,861,093
U01 · FY2020 · MH
The National Drug Abuse Clinical Trials Network: New England Consortium Node$10,852,537
UG1 · FY2020 · DA
A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseases$10,834,632
UG3 · FY2024 · TR
Yale Clinical and Translational Science Award$10,737,719
UL1 · FY2024 · TR